US · Healthcare · Biotechnology
EPS came in at -0.40 against a street estimate of -0.28 — a miss of 42.9%.
Analysts rate Valneva SE ADR a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $12.25.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 2.42% |
| Novo A/S | 1.12% |
| Vivo Capital, LLC | 0.80% |
| General American Investors Co Inc | 0.37% |
| Millennium Management LLC | 0.14% |
| Wells Fargo & Co | 0.08% |
| Morgan Stanley - Brokerage Accounts | 0.05% |
| Ironwood Investment Management LLC | 0.03% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Valneva SE ADR — free to start.
Google PlayApp StoreData updated 2026-09-18.